As a result, the company has adjusted its projected Covid-19 vaccine revenue for 2023 to approximately 4 billion euros ($4.29 billion), down from the initial estimate of around 5 billion euros. The regulatory approval process has encountered unforeseen delays, impacting the timeline for vaccine distribution and subsequent revenue generation. A: BioNTech cited delays in regulatory approvals and Pfizer’s inventory write-downs as the primary factors contributing to the decrease in revenue expectations. A: The company has revised its research and development investment, lowering the target range from 2.40 billion to 2.60 billion euros to between 1.80 billion and 2.00 billion euros. A: BioNTech remains dedicated to scientific innovation and the development of effective vaccines, despite the revised revenue expectations.

Source: Wall Street Journal November 06, 2023 12:03 UTC